Slide 1: Kwality Pharmaceuticals Ltd Investor Presentation FY25
Kwality Pharmaceuticals Ltd India’s fastest growing manufacturer of complex injectables INVESTOR PRESENTATION FY25
Slide 2: Disclaimer
DISCLAMER Some of the statements made in this presentation are forward-looking statements and are hased on the current beliefs, assumptions, expectations, estimates, objectives and projections of the directors and management of Kwality Pharmaceutical Limited about its business, the industry and mark
Slide 3: Table of Contents
TABLE OF CONTENTS Title Company Overview KPL at a Glance Journey so far Promoters Profile Plants of KPL Differentiated Capabilities Revenue Split Key markets by sale Complex Injectables development Biologics R&D and Manufacturing excellence Financial Metrics Growth strategy and Financials Page
Slide 4: Company Overview
COMPANY OVERVIEW G) Kwality Pharma : A legacy of quality and growth For over 40 years, Kwality Pharma has been a trusted name in the healthcare sector, synonymous with unparalleled growth and reliability. We are driven by a customer centric vision, committed to delivering high quality products. JASS
Slide 5: Kwality Pharma at a Glance
KWALITY PHARMA AT A GLANCE Manufacturing Excellence £& fu) Let, IS Product Specialization Development and supply of affordable In-hous' ah Complex Injectables R&D Capabilities e research and development expertise Regulatory Accreditations Accredited by global regulatory authorities Manufacturing Fac
Slide 6: More Than Three Decade Legacy of Experience and Trust
MORE THAN THREE DECADE LEGACY OF EXPERIENCE AND TRUST 2018 2022 2024 Manufacturing Facility Upgradation Established Beta lactam Unit“? Initiated Preclinical programme for Migrated to Main Board of KPL 1’st Biologics Journey so far... PIC/s GMP for Injectable facility Bee a . Successful approval and
Slide 7: Promoters Profile
PROMOTERS PROFILE Mr. Ramesh Arora, Managing Director A respected leader in the pharmaceutical industry, Ramesh Arora has played a pivotal role in transforming Kwality Pharma Ltd into a globally trusted brand. With decades of experience, he drives strategic growth and mentors the next generation of
Slide 8: Amritsar Plant - Comprehensive Offerings with Advanced Manufacturing Capabilities
AMRITSAR PLANT - Comprehensive Offerings with Advanced Manufacturing Capabilities x E : bell.) ag wd xe me == Se a a eo aE a == f==—$-—-]--I--BAs 38 > see - — e- -| Soe” = 8 iB 7 Oral Solids — Tab/Capsule, Suppositories Oral Solids — Tab/Capsule Dmg Product — PFS Ointments/Creams, Oral Liquids Powde
Slide 9: Himachal Plant: High End Technology Driven campus
HIMACHAL PLANT : High End Technology Driven campus in the lap of nature Unit 3 Oncology =" Capabilities Oral Solids Tab/Capsule Injectables (Vials) (Liquid/Lyophilized) Tablets — 380 Million Capacities Capsules — 38 Million Liquid Injection (Non peptide) — 47 Million =a Lyophilized Powder & Cake — 1
Slide 10: Differentiated Capabilities
DIFFERENTIATED CAPABILITIES Liposomal Pegylated Injectables © £4 Long-acting Injectables Tissue Targeting ~ Sustained Drug Release Intracellular Targeting ~ Peptide-based Injections ' Increased Exposure Time "> Polymeric Microspheres Drug Solubilization ~~ In-situ Forming Depots Emulsion Technology
Slide 11: Revenue Split
REVENUE SPLIT (G) REVENUE (INR CR) 307 ee Growing with CAGR (3Yrs) — 21.4% FY23 FY24 Facility Wise Sales Break Up Segment Wise Sales Break Up Unit Wise Sales Break Up f w Injectable “a - = Oral Solids = Oral Liquids = External Preparations = Oph/Otics 10 ; : ® Oral Powders = Amritsar = Himachal gUni
Slide 12: Geographic Segmentation
GEOGRAPHIC SEGEMENTATION = ¢ I / \ / ‘ GCC/MENA ah } \ ; \ ry \ ri \ t \ 1 \ i - ' \ i \ i ay V ‘ fi South and Central [i _— America \ ‘ ‘ i Middle East a ul \ LY AY YJ a i Ul a Ul Ul i Operating in 70+ + Markets Domestic Russia/CIS % of sales 11
Slide 13: Championing the art of Complex Injectable Development
Championing the art of Complex Injectable Development Few of them are.... mk Propofol Emulsion 10 mg/ ml (Gx Diprivane) Amphotericin B Liposomal 50 mg (Gx Ambisome, Gilead) Leuprolide Depot 3.75mg. 7.5 mg, 11.25mg, 22.5 mg, 30 mg (Gx Leupron Depot) } @ Nano- 6, x) © EU Manufacturer (KPL Strategic Pa
Slide 14: Commercialization: Biologics
Commercialization Ready by end of Q3 FY26 BIOLOGICS @ KPL Erythropoietin Programme Clinical Approval Secure regulatory approval linical Trials Market Gap Unmet need for Erythropoietin Initiate Trials Begin clinical testing Accessible Solution Affordable Erythropoietin available KPL Biological Snapsh
Slide 15: Striving for Excellence
STRIVING FOR EXCELLENCE Research Excellence Manufacturing Excellence Our R&D division is at the forefront of Pharmaceutical All manufacturing units are equipped with Innovation. With a team of experienced scientist, we focus state of the art equipment and adhering to on developing innovative drug de
Slide 16: Financial Metrics
FINANCIAL METRICS Revenue (INR CR) EBITDA (INR CR) 370 80 60 FY?2 FY?4 AIS FY23 FY24 FY25 PAT (INR CR) EPS “0 38.36 po a all Ap AO oe AOR © aa 2276 y ee 18.16 FY23 Fy24 Fy25 FY23 FY24 Fy25 15
Slide 17: KPL Growth Strategy and Financials
KPL Growth strategy and Financials © Revenue from =_ Revenue Target Operations 251 307 370 Aiming tor 500 crores in revenue Total Expenses 190 241 290 » | A EBITDA Margins EBITDA 60 66 80 O |Projecting margins between 22— Finance cost 6 10 10 25% oe _ ° Initiati Depreciation 15 20 18 tevic Initiati
Slide 18: Thank You
THANK YOU Kwality Pharmaceuticals Limited Head Office Address: 6 Milestone, Majitha Road, Amrilsar-143601, Punjab, India Email: ujjvalseth@kwalitypharma.com cs alitypharma.com info@kwalitypharma.com